Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis-the PMEP trial: Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Jennings, Mark T ^a   Boyle, Michael P ^a   Weaver, David ^b   Callahan, Karen A ^a   Dasenbrook, Elliott C ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cystic fibrosis; MRSA; Randomized controlled trial; Vancomycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHLORHEXIDINE; COTRIMOXAZOLE; DOXYCYCLINE; PLACEBO; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; COMPLICATION; DRUG EFFECTS; FOLLOW UP; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MICROBIOLOGY; NEBULIZER; REMISSION; STAPHYLOCOCCAL INFECTIONS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NEBULIZERS AND VAPORIZERS; REMISSION INDUCTION; RESEARCH DESIGN; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84902975826     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-223     Document Type: Article

References (13)

1. Boyle MP. Adult cystic fibrosis. JAMA 2007, 298:1787-1793. 10.1001/jama.298.15.1787, 17940235.
2. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry, 2012 Annual Data Report 2013, Bethesda, MD: Cystic Fibrosis Foundation, Cystic Fibrosis Foundation.
3. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821. 10.1164/rccm.200802-327OC, 18669817.
4. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303:2386-2392. 10.1001/jama.2010.791, 20551409.
5. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182:627-632. 10.1164/rccm.200909-1421OC, 20463179.
6. Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 2004, 56:208-214. 10.1016/j.jhin.2003.12.003, 15003669.
7. Macfarlane M, Leavy A, McCaughan J, Fair R, Reid AJ. Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007, 65:231-236. 10.1016/j.jhin.2006.10.011, 17178427.
8. Solis A, Brown D, Hughes J, Van Saene HK, Heaf DP. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003, 36:189-195. 10.1002/ppul.10231, 12910579.
9. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, Webb AK, Jones AM. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010, 9:104-109. 10.1016/j.jcf.2009.11.009, 20051329.
10. Generali J, Cada D. Vancomycin: aerosolization. Hosp Pharm 2004, 39:638-647.
11. Shirai M, Ide K, Sato M. Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus. Nihon Kyobu Shikkan Gakkai Zasshi 1995, 33:1233.
12. Jennings M, Bucur C, Boyle MP, Konstan M, Dasenbrook EC. Poster session abstracts: safety and pharmacokinetics of inhaled vancomycin in individuals with cystic fibrosis. Pediatr Pulmonol 2012, 47:223-446.
13. Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012, 12. CD001912.